Coyne Terrance P.
SEC CIK 1814876 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma plc | EVP, CFO | 0 | — | $46.18M | 25 | 2022-08-01 | 2026-08-13 |
Most active insiders at RPRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Coyne Terrance P. | EVP, CFO | — | $38.96M |
| 2 | Hite Christopher | EVP, Vice COB | — | $27.36M |
| 3 | Lloyd George W. | EVP, CLO, Investments | — | $13.81M |
| 4 | Urist Marshall | EVP, Research, Investments | — | $12.07M |
| 5 | Norden Gregory | Dir | — | $161.4K |
| 6 | Engelbert Catherine M. | Dir | — | — |
| 7 | Ho Carole | Dir | — | — |
| 8 | Coric Vlad | Dir | — | — |
| 9 | Bassler Bonnie L | Dir | — | — |
| 10 | Legorreta Pablo G. | CEO, COB, Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2026-08-17 17:01 | 2026-08-13 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $58.68 | -11.0K | 0 | -100% | -$645.6K |
| DI | 2026-08-07 17:24 | 2026-08-05 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | A - Grant | $0.00 | +11.0K | 11.0K | New | $0 |
| TI | 2026-05-28 16:48 | 2026-05-26 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $53.98 | -64.4K | 0 | -100% | -$3.48M |
| I | 2026-05-08 17:14 | 2026-05-06 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | A - Grant | $0.00 | +24.3K | 64.4K | +60% | $0 |
| MTI | 2026-04-30 17:54 | 2026-04-28 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $49.78 | -34.8K | 40.1K | -46% | -$1.73M |
| MTI | 2026-04-02 17:58 | 2026-04-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $48.33 | -34.8K | 32.9K | -51% | -$1.68M |
| MI | 2026-03-25 | 2026-03-23 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $45.53 | -34.8K | 43.9K | -44% | -$1.58M |
| MI | 2026-03-04 | 2026-03-02 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $46.78 | -34.8K | 45.8K | -43% | -$1.63M |
| MI | 2026-02-25 | 2026-02-23 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $45.32 | -34.8K | 47.6K | -42% | -$1.58M |
| I | 2026-02-13 | 2026-02-11 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | A - Grant | $0.00 | +26.6K | 49.5K | +116% | $0 |
| MI | 2026-02-04 | 2026-02-02+ | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $42.54 | -243.5K | 183.7K | -57% | -$10.36M |
| MI | 2026-01-23 | 2026-01-20 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.35 | -69.6K | 36.0K | -66% | -$2.74M |
| MI | 2026-01-06 | 2026-01-02 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $38.42 | -69.6K | 460.8K | -13% | -$2.67M |
| MI | 2025-12-17 | 2025-12-15 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $38.36 | -69.6K | 526.7K | -12% | -$2.67M |
| MI | 2025-12-03 | 2025-12-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.87 | -69.6K | 592.5K | -11% | -$2.77M |
| MI | 2025-11-26 | 2025-11-24 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $38.55 | -69.6K | 658.3K | -10% | -$2.68M |
| MI | 2025-11-19 | 2025-11-17 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.30 | -69.6K | 54.8K | -56% | -$2.74M |
| I | 2025-11-07 | 2025-11-05 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | A - Grant | $0.00 | +6,168 | 58.5K | +12% | $0 |
| DI | 2025-08-08 | 2025-08-06 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | A - Grant | $0.00 | +3,696 | 52.3K | +8% | $0 |
| I | 2025-05-09 | 2025-05-08 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | A - Grant | $0.00 | +48.6K | 48.6K | New | $0 |
| MI | 2023-08-11 | 2023-08-09+ | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $30.73 | -75.0K | 827.5K | -8% | -$2.31M |
| MI | 2023-07-14 | 2023-07-12+ | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $31.00 | -75.0K | 865.0K | -8% | -$2.33M |
| I | 2022-11-10 | 2022-11-08 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $43.47 | -24.5K | 940.0K | -3% | -$1.07M |
| I | 2022-11-04 | 2022-11-02 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $43.06 | -5,500 | 964.5K | -0.6% | -$236.8K |
| I | 2022-08-03 | 2022-08-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP, CFO | S - Sale | $43.19 | -30.0K | 970.0K | -3% | -$1.30M |
Purchase Sale Sale after option exercise All abbreviations